Non-Hodgkin’s lymphoma (NHL) is a heterogenous malignancy with many different subtypes. Although patients initially respond to treatments, approximately 40% of this cohort will subsequently relapse. After exhausting several lines of treatment, determining the next option is largely empirical. There is a need to develop approaches that are able to identify personalized therapies. There are existing ex vivo approaches that use single-drug sensitivity assays but lack the ability to truly evaluate drug combinations. In this clinical study, we aim to evaluate the potential of an ex vivo combinatorial drug sensitivity platform, Optim.AI™, to identify therapeutic options for relapsed/refractory (RR) NHL.
Would you like to read the full poster including its images?